Syndax PharmaceuticalsSNDX
SNDX
About: Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Employees: 184
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
129% more call options, than puts
Call options by funds: $18.1M | Put options by funds: $7.88M
44% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 61
27% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 26
25% more funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 10 (+2) [Q1 2025]
2.53% more ownership
Funds ownership: 114.85% [Q4 2024] → 117.38% (+2.53%) [Q1 2025]
1% more funds holding
Funds holding: 215 [Q4 2024] → 218 (+3) [Q1 2025]
3% less capital invested
Capital invested by funds: $1.3B [Q4 2024] → $1.26B (-$41M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
66%
upside
Avg. target
$30
193%
upside
High target
$41
300%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Scotiabank George Farmer | 66%upside $17 | Sector Perform Maintained | 6 May 2025 |
Guggenheim Michael Schmidt | 212%upside $32 | Buy Reiterated | 6 May 2025 |
JP Morgan Anupam Rama | 300%upside $41 | Overweight Maintained | 20 Mar 2025 |
Financial journalist opinion
Based on 4 articles about SNDX published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –
Neutral
GlobeNewsWire
2 days ago
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ORR in Ph 1 patients with R/R NUP98r AML – NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced new data from the pivotal AUGMENT-101 trial of Revuforj® (revumenib), the Company's first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) and NUP98-rearranged (NUP98r) acute myeloid leukemia (AML). The data are being presented in posters at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy and virtually.
Neutral
GlobeNewsWire
1 week ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2025 the Company granted inducement awards to purchase up to 119,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Neutral
GlobeNewsWire
2 weeks ago
Syndax Announces Participation in June Investor Conferences
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
1 month ago
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r –
Neutral
GlobeNewsWire
1 month ago
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics -
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 month ago
Syndax Announces Participation in May Investor Conferences
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Bank of America Merrill Lynch Vegas Health Care Conference with a fireside chat on Thursday, May 15, 2025, at 9:20 a.m.
Neutral
GlobeNewsWire
1 month ago
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML submitted in April 2025 – NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, a first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) have been published in Blood. “We are thrilled to publish the first positive pivotal dataset in patients with an NPM1 mutation, the most common genetic alteration observed in AML,” said Neil Gallagher, M.D.
Neutral
Seeking Alpha
1 month ago
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - Chief Executive Officer and Director Steve Closter - Chief Commercial Officer Neil Gallagher - President and Head of R&D Keith Goldan - Chief Financial Officer Anjali Ganguli - Chief Strategy Officer Conference Call Participants Jason Zemansky - Bank of America Ellen Horste - TD Cowen Peter Lawson - Barclays Michael Schmidt - Guggenheim David Dai - UBS Yigal Nochomovitz - Citi Kalpit Patel - B. Riley Securities Jeet Mukherjee - BTIG Salim Syed - Mizuho George Farmer - Scotiabank Operator Good day, everyone, and welcome to the Syndax First Quarter 2025 Earnings Conference Call.
Charts implemented using Lightweight Charts™